Maze (MAZE)
Develops small-molecule therapies guided by human genetics for kidney and metabolic diseases.
Something off on this page? Send us feedback.
Uses the Compass platform to turn human genetic variation into small-molecule programs for kidney and metabolic diseases. Its pipeline centers on MZE829 and MZE782, with Pompe disease program MZE001 partnered to Shionogi and the business still pre-commercial.
Built around the Compass platform, the business uses human genetics and variant functionalization to identify disease drivers and design small-molecule precision medicines. Current work is focused on kidney and metabolic diseases rather than marketed products.
MZE829 is the most advanced wholly owned program for APOL1-mediated kidney disease. MZE782 targets PKU and chronic kidney disease, while MZE001 for Pompe disease is partnered with Shionogi.
Operations are anchored in South San Francisco and reported as a single operating segment. Execution depends on clinical development, regulatory approval, intellectual property protection, and financing or partnership capital because there are no approved commercial products and no product revenue.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Apr 14, 2026 | Truist Financial | Target | $68 | $64 | |
| Mar 17, 2026 | Truist Financial | Target | $68 | ||
| Mar 10, 2026 | Mizuho Securities | Target | $97 | ||
| Jan 19, 2026 | BTIG | Target | $30 | $46 | |
| Dec 19, 2025 | Guggenheim | Target | $34 | $46 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $411.1M · Total debt $60.4M · Total assets $531.6M · Shareholders' equity $453.1M
- Revenue
- $0
- Operating income
- −$48.0M
- Net income
- −$44.7M
No dividends on record.
| Institutions176 holders · as of Mar 31, 2026 · largest filers plus last quarter's tail | ≈ 92.31% | 51.28M shares | |
| Insiders6 holders · as of Aug 31, 2026 | 2.16% | 1.20M shares | |
| Strategic holders1 holder · as of Feb 13, 2026 | 8.05% | 4.47M shares | |
| Adds to | 102.52% |
55.55M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 102.52%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Frazier Life Sciences Management, L.P.Institution | 8.22% | 4.57M | 13Fas of Mar 31, 2026 |
TRV GP Iv, LLCInstitution | 8.05% | 4.47M | 13Fas of Mar 31, 2026 |
Third Rock Ventures IV, L.P.1,2Strategic10 percent owner | 8.05% | 4.47M | 13Gfiled Feb 13, 2026 ↗ |
Frazier Life Sciences Public Fund, L.P.Institution | 7.82% | 4.34M | 13Gfiled Feb 13, 2026 ↗ |
Arch Venture Management, LLCInstitution | 7.42% | 4.12M | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
- Third Rock Ventures IV, L.P.'s transaction reports restate only vehicles that traded; the 2026 ownership statement (4.47M) is used instead.
- Third Rock Ventures IV, L.P. reports a block also reported by Frazier Life Sciences Management, L.P.; it is counted once, under Frazier Life Sciences Management, L.P.
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 28, 2026 | Atul Dandekar | officer: CSBO | −7,500 | $27.58 |
| Aug 13, 2026 | Harold Bernstein | officer: President, R&D & CMO | −16,142 | $27.61 |
| Aug 3, 2026 | Jason V. Coloma | director, officer: Chief Executive Officer | −34,501 | $26.73 |
| Jul 29, 2026 | Atul Dandekar | officer: CSBO | −7,500 | $27.34 |
| Jul 1, 2026 | Jason V. Coloma | director, officer: Chief Executive Officer | −34,501 | $29.98 |
- Vertex Pharmaceuticals
Direct APOL1 kidney rival with inaxaplin in Phase 2/3
- BioMarin
PKU and Pompe overlap through PALYNZIQ and Pombiliti + Opfolda
- AstraZeneca (ADR)
CKD standard-of-care overlap through Farxiga and renal pipeline
- Novo Nordisk (ADR)
GLP-1 CKD/metabolic pressure through Ozempic and semaglutide
- Sanofi (ADR)
Pompe incumbent with Nexviazyme and long-running ERT franchise
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Maze | $26.70 | +0.64% | $1.48B | — | — | 73.9 | — |
| Vertex Pharmaceuticals | $555.40 | −0.23% | $141.31B | 32.4 | 28.6 | 11.2 | +12.5% |
| BioMarin | $67.19 | +0.27% | $12.94B | 171.7 | 10.8 | 3.8 | +19.9% |
| AstraZeneca (ADR) | $163.48 | +1.13% | $250.67B | 24.3 | 15.2 | 4.1 | +6.4% |
| Novo Nordisk (ADR) | $47.46 | +1.51% | $207.69B | 11.5 | 18.9 | 4.1 | +0.0% |
| Sanofi (ADR) | $44.52 | +0.12% | $106.78B | 78.2 | — | 1.9 | +11.2% |
| Median | 32.4 | 17.0 | 4.1 | +11.2% |